A Phase 3 trial of Avastin (bevacizumab) in combination with docetaxel and prednisone in men with late-stage prostate cancer has failed to meet its primary endpoint of extending overall survival, the Roche Group announced.
Cellzome Inc said that it has secured a new drug discovery deal with GlaxoSmithKline under which the companies will seek to identify small-molecule drugs against epigenetic targets. Cellzome will receive €33 million upfront.
Novartis AG is raising $5 billion with a three-tranche bond issue to finance part of its pending acquisition of Alcon Inc, a large eye-care company with sales of approximately $6.5 billion in 2009.
A French producer of therapeutic vaccines for cancer has raised €13.1 million from private and public sources in order to bring its lead product, a therapeutic human papillomavirus vaccine, into the clinic.
Ark Therapeutics Group Plc has dropped its appeal against a negative opinion from the European Medicines Agency for its gene therapy for brain cancer, Cerepro. It also announced that it is in talks about a possible takeover of the company. Ark disclosed the developments on 9 March 2010.
Genmab A/S said that its antibody for head and neck cancer, zalutumumab, has failed to show overall survival in a Phase 3 study in which the drug was being tested in combination with best supportive care versus best standard care alone.
AstraZeneca Plc said that its candidate drug, Recentin (cediranib), for patients with first-line metastatic colorectal cancer, failed to meet its primary endpoint of non-inferiority in progression-free survival in a Phase 2/3 trial.
The Roche Group and Biogen Idec of the US have suspended clinical trials of the humanized anti-CD20 monoclonal antibody, ocrelizumab, in four rheumatoid arthritis trials because of safety issues. The drug was in Phase 2 and 3 trials.
BioAlliance Pharma SA is looking ahead to three possibly transforming events in the second quarter of 2010 that could secure its standing as a recognised specialty pharmaceutical company in Europe.
An investigational drug for patients with Alzheimer’s disease, Dimebon (latrepirdine), has failed in a Phase 3 trial because it could not show statistically significant improvements in patients compared with placebo for cognition and global function.